更正：HP1β是乳腺癌预后和PARP抑制剂治疗的生物标志物。
Correction: HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.
作者信息
Lee Young-Ho, Liu Xiyong, Qiu Fuming, O'Connor Timothy R, Yen Yun, Ann David K
出版信息
PLoS One. 2015 Apr 13;10(4):e0124853. doi: 10.1371/journal.pone.0124853. eCollection 2015.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0121207.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0121207。]
相似文献
1
Correction: HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.更正：HP1β是乳腺癌预后和PARP抑制剂治疗的生物标志物。
PLoS One. 2015 Apr 13;10(4):e0124853. doi: 10.1371/journal.pone.0124853. eCollection 2015.
2
Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.更正：使用三种不同药物组合克服癌细胞对PARP-1抑制剂的耐药性
PLoS One. 2016 Aug 22;11(8):e0161799. doi: 10.1371/journal.pone.0161799. eCollection 2016.
3
Correction: galectin-3 as a marker and potential therapeutic target in breast cancer.更正：半乳糖凝集素-3作为乳腺癌的标志物和潜在治疗靶点。
PLoS One. 2015 Jan 26;10(1):e0116994. doi: 10.1371/journal.pone.0116994. eCollection 2015.
4
Correction: breast cancer screening in Saudi Arabia: free but almost no takers.更正：沙特阿拉伯的乳腺癌筛查：免费但几乎无人参与。
PLoS One. 2015 Apr 8;10(4):e0124850. doi: 10.1371/journal.pone.0124850. eCollection 2015.
5
Correction: challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.更正：开发血管生成抑制剂有效生物标志物面临的挑战：莫替沙尼的经验。
PLoS One. 2015 Mar 26;10(3):e0121162. doi: 10.1371/journal.pone.0121162. eCollection 2015.
6
Correction: IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer.更正：白细胞介素-6表达调节膀胱癌的致瘤性并与预后相关。
PLoS One. 2016 May 16;11(5):e0155774. doi: 10.1371/journal.pone.0155774. eCollection 2016.
7
Correction: MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer.更正：MRI背景实质强化与乳腺癌无关。
PLoS One. 2016 Sep 8;11(9):e0162936. doi: 10.1371/journal.pone.0162936. eCollection 2016.
8
Correction: Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis.更正：三阴性乳腺癌中eEF1A2蛋白表达水平升高与预后不良相关。
PLoS One. 2019 Dec 19;14(12):e0227068. doi: 10.1371/journal.pone.0227068. eCollection 2019.
9
Correction: Detection of a Serum Siderophore by LC-MS/ MS as a Potential Biomarker of Invasive Aspergillosis.更正：通过液相色谱-质谱联用技术检测血清铁载体作为侵袭性曲霉病的潜在生物标志物
PLoS One. 2016 May 10;11(5):e0155451. doi: 10.1371/journal.pone.0155451. eCollection 2016.
10
Correction: chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications.更正：乳腺癌幸存者经历的化疗脑：一项调查研究与护理意义的元民族志研究。
PLoS One. 2015 Feb 3;10(2):e0117740. doi: 10.1371/journal.pone.0117740. eCollection 2015.
引用本文的文献
1
Prognostic genes of breast cancer revealed by gene co-expression network analysis.通过基因共表达网络分析揭示的乳腺癌预后基因
Oncol Lett. 2017 Oct;14(4):4535-4542. doi: 10.3892/ol.2017.6779. Epub 2017 Aug 21.
本文引用的文献
1
HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.HP1β是乳腺癌预后和PARP抑制剂治疗的生物标志物。
PLoS One. 2015 Mar 13;10(3):e0121207. doi: 10.1371/journal.pone.0121207. eCollection 2015.
Zotero 插件